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Background. Atherosclerotic vascular disease is the leading
cause of death in patients with diabetes mellitus and end-stage
renal disease. Advanced glycation end products (AGEs) are
strongly suggested to be involved in the pathogenesis of athero-
sclerosis in these patients who also frequently experience infec-
tious complications. We hypothesized that the interaction of
AGEs and inflammatory mediators contributes to the up-regula-
tion of endothelial cell activation.
Methods. We investigated the effect of advanced glycated
fibronectin in the presence or absence of inflammatory stimuli on
the endothelial cell surface and mRNA expression of cell adhe-
sion molecules. Furthermore, the influence of advanced glycated
fibronectin on the transendothelial migration pattern of polymor-
phonuclear cells was analyzed.
Results. Exposure to advanced glycated fibronectin together
with inflammatory stimuli such as interleukin (IL)-1a, tumor
necrosis factor-a (TNF-a) or lipopolysaccharide (LPS) led to a
significant increase in the surface expression of the cell adhesion
molecules E-selectin, ICAM-1, VCAM-1 and PECAM-1 on en-
dothelial cells. Soluble AGEs in combination with advanced
glycated fibronectin significantly enhanced the endothelial cell
surface expression of ICAM-1, VCAM-1 and PECAM-1, whereas
this was not the case for E-selectin. At the transcriptional level
short-time exposure of endothelial cells to advanced glycated
fibronectin and inflammatory mediators resulted in an increased
expression of E-selectin, ICAM-1 and VCAM-1 mRNA levels,
whereas PECAM-1 repeatedly showed a significant decrease of
gene transcript levels. An increase of mRNA levels was also
observed for E-selectin, ICAM-1, VCAM-1 and PECAM-1 fol-
lowing incubation with a combination of advanced glycated fi-
bronectin and soluble advanced glycation end-products. Further-
more, polymorphonuclear cells responded with a sevenfold
increase in transendothelial migration following exposure of
endothelial cells to advanced glycated fibronectin and inflamma-
tory mediators.
Conclusions. These results suggest that the combination of
matrix glycation and inflammation up-regulates the activation of
the endothelial cell adhesion cascade, a mechanism that might
contribute to the increased burden of atherosclerotic morbidity
and mortality in patients suffering from diabetes mellitus or
chronic renal failure.
The incidence of vascular disease morbidity and mortal-
ity is manifold increased in patients with diabetes mellitus
and in patients with end-stage renal failure [1–3]. One key
event in the development of atherosclerosis is the adhesion
of leukocytes to the vascular endothelium [4]. Cytokine
inducible cellular adhesion molecules (CAM) expressed on
the surface of endothelial cells including E-selectin, inter-
cellular CAM-1 (ICAM-1), vascular CAM-1 (VCAM-1),
and platelet-endothelial CAM (PECAM) have been shown
to participate in the atherosclerotic plaque formation
[5–13]. Additionally, advanced glycation end products
(AGEs) have been suggested to be involved in the patho-
genesis of atherosclerosis, since both circulating and con-
nective tissue AGEs have been identified in patients suf-
fering from diabetes mellitus or end-stage renal failure [14,
15].
AGEs represent a heterogeneous group of metabolically
altered substrates that accumulate during long-term hyper-
glycemia. Advanced glycation starts with a non-enzymatic
condensation reaction between circulating blood glucose
and amino groups, forming slowly reversible Amadori
products. Upon prolonged exposure to elevated plasma
glucose levels, these early glycated products are trans-
formed into AGEs that are now irreversibly bound to
proteins, lipids and nucleic acids [16]. Thus, AGE-forma-
tion alters long-lived molecules in particular, such as extra-
cellular matrix components, and increases with age.
One candidate extracellular matrix protein that might be
altered by advanced glycation is fibronectin, a component
of the basal membrane of the blood vessel wall that is
covered by endothelial cells. Endothelial cells are able to
interact with AGEs via specific AGE receptors resulting in
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an increased vascular permeability and the up-regulation of
endothelial cell surface procoagulants [17]. Furthermore,
AGEs quench nitric oxide and thus interfere with endothe-
lium-dependent vascular relaxation [18].
Since AGEs are strongly suggested to be involved in the
pathogenesis of atherosclerosis in patients with diabetes
mellitus and renal failure who also frequently experience
infectious complications [19, 20], the hypothesis was raised
that the interaction of AGEs and inflammatory mediators
enhances the up-regulation of endothelial cell adhesion
molecules and the transendothelial migration of leuko-
cytes. This interaction could contribute to the multifactorial
acceleration of atherosclerosis in these patients who fre-
quently experience episodes of infections.
METHODS
Reagents and antibodies
Fibronectin and endothelial cell growth supplement were
purchased from Collaborative Biomedical Products (Bed-
ford, MA, USA). Fetal calf serum, collagenase type I,
Hank’s solution, Dulbecco’s phosphate-buffered saline
(PBS) and RPMI 1640 medium were obtained from Gibco
Laboratories (Grand Island, NY, USA). Ficoll-Paque was
obtained from Pharmacia (Uppsala, Sweden). Bovine se-
rum albumin, b2-microglobulin, complete Freund’s adju-
vant, fluorescein isothiocyanate (FITC), RNAse and endo-
toxin of E. coli serotype 026:B6 were purchased from Sigma
Chemical Co. (St. Louis, MO, USA). Human IgG was from
Biochemie GmbH (Vienna, Austria). Glucose-6-phosphate
and 2,29-Azinobis-3-ethylbenzthiazoline-sulfonic acid
(ABTS) were from Boehringer Mannheim (Mannheim,
Germany). RNazol-B was obtained from Biotech Lab. Inc.
(Houston, TX, USA). Calcein AM was purchased from
Molecular Probes (Eugene, OR, USA). The oligonucleo-
tide primers were purchased from Pharmacia (Vienna,
Austria) and are summarized in Table 1. Ampli-Taq DNA-
Polymerase was from Perkin Elmer Cetus (Norwalk, CT,
USA). The 6% polyacrylamide mini gels were from Novex
(San Diego, CA, USA). The limulus assay (Coatest Endo-
toxin) was obtained from Boehringer Ingelheim (In-
gelheim, Germany).
The antibodies 5.6E (PECAM), 84H10 (ICAM-1), 1.2B6
(E-selectin), 1G2 (endoglin), 1G11 (VCAM-1) and 4F9
(von Willebrand factor) were obtained from Immunotech
(Marseille Cedex, France). Interleukin-1a (IL-1a), tumor
necrosis factor-a (TNF-a) and blocking antibodies BBIG-I
1 (ICAM-1), BBIG-E4 (E-selectin) and BBIG-V1
(VCAM-1) were supplied by R&D Systems (Minneapolis,
MN, USA). FITC labeled goat F(ab)2 anti-mouse
IgG1IgM and non-specific anti-IgG11IgG2a antibodies
were from An der Grub (Vienna, Austria).
Preparation of advanced glycated fibronectin
Advanced glycated fibronectin (AGE-fibronectin) was
prepared using fibronectin (1 mg/ml) in a reaction mixture
containing 5 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5 M
glucose-6-phosphate (G-6-P) and proteinase inhibitors (1
mM phenyl-methyl-sulfonyl-fluoride, 5 mM EDTA (pH 8.0),
trypsin inhibitor 50 mg/ml, aprotinin 2 mg/ml, 1 mM amin-
ocaproic acid and 0.02% sodium-azide). Native fibronectin,
which served as a control, was incubated under identical
conditions without G-6-P. Using Limulus assay, the lipo-
polysaccharide (LPS) level in the AGE-fibronectin stock
solution was determined to be , 0.6 ng/ml, which was
further diluted (1:40). Only AGE-fibronectin without de-
tectable LPS was used in all experiments. Quality controls
to assess formation of AGE-fibronectin included the mea-
surement of the fluorescence intensity (at 370 nm and 440
nm, respectively) using a spectrofluorometer (Shimadzu
RF-551; the specific fluorescence intensity of AGE-fi-
bronectin used in all experiments was 15000 RFUs, native
fibronectin showed no fluorescence) and the analysis of the
Table 1. Relative surface and mRNA expression of E-selectin, ICAM-1, VCAM-1 and PECAM cultured on native fibronectin (N-FN) or AGE-
fibronectin (AGE-FN) and stimulated with IL-1a, TNF-a, LPS or AGE-albumin (sAGE) following different times of incubation (in comparison to
culture of cells on native fibronectin in medium; n.d., not done).
Expression of Location hours N-FN1IL-1a N-FN1TNFa N-FN1LPS N-FN1sAGE AGE-FN-Co AGE-FN1IL-1a
E-selectin surface, 4 hr 380 6 27 229 6 18 366 6 29 112 6 6 130 6 15 1260 6 113
surface, 18 hr 184 6 30 124 6 17 123 6 25 80 6 5 91 6 10 302 6 30
mRNA, 2.5 hr 292 6 9 n.d. n.d. 317 6 69 237 6 62 570 6 121
mRNA, 10 hr 483 6 42 n.d. n.d. 106 6 25 120 6 23 684 6 155
ICAM-1 surface, 4 hr 185 6 14 162 6 14 187 6 17 104 6 2 141 6 5 259 6 29
surface, 18 hr 368 6 23 288 6 19 341 6 18 100 6 6 112 6 6 468 6 42
mRNA, 2.5 hr 269 6 29 n.d. n.d. 144 6 29 132 6 22 421 6 52
mRNA, 10 hr 400 6 24 n.d. n.d. 109 6 15 83 6 11 368 6 18
VCAM-1 surface, 4 hr 556 6 46 536 6 41 611 6 46 124 6 8 167 6 14 1071 6 96
surface, 18 hr 963 6 106 757 6 74 776 6 84 119 6 11 130 6 13 1416 6 148
mRNA, 2.5 hr 80 6 21 n.d. n.d. 193 6 48 169 6 30 299 6 61
mRNA, 10 hr 537 6 34 n.d. n.d. 171 6 22 137 6 21 435 6 49
PECAM surface, 4 hr 102 6 4 101 6 3 94 6 4 102 6 2 122 6 6 119 6 3
surface, 18 hr 107 6 5 106 6 5 103 6 5 91 6 3 117 6 3 132 6 10
mRNA, 2.5 hr 60 6 10 n.d. n.d. 91 6 19 101 6 15 59 6 13
mRNA, 10 hr 46 6 6 n.d. n.d. 91 6 5 91 6 5 40 6 5
Abbreviations are in the Appendix.
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inhibition properties of AGE antibody binding in the solid
phase immunoassay (as described below).
Generation of anti-AGE antibodies using AGE-RNAse
AGE-RNAse was prepared by incubating RNAse (25
mg/ml) in PBS (pH 7.4) containing 0.5 M G-6-P, 0.1%
sodium-azide, 100 U/ml penicillin and 100 mg/ml strepto-
mycin for five weeks at 37°C under sterile conditions. Prior
to incubation the reaction mixture was passed through a
Detoxigel column (Pierce, Rockford, IL, USA) to eliminate
contaminating LPS. At the end of the incubation, unbound
G-6-P was removed by dialysis against PBS.
For the preparation of anti-AGE antibodies, white fe-
male New Zealand rabbits were immunized with 10 mg/ml
or 25 mg/ml of AGE-RNAse emulsified in an equal volume
of complete Freund’s adjuvant. Two hundred and fifty
microliters were injected subcutaneously every two weeks
at two different sites of the back of the animals. A total of
six injections were given. After the second injection blood
was collected for the determination of antibody titers prior
to each injection. High titers were observed ten weeks after
the immunization. AGE-antibody titers were determined
by a solid-phase assay as described below.
Advanced glycated end product immunoassay
Advanced glycated albumin (AGE-albumin) was pre-
pared using the same conditions as described above for
AGE-RNAse, but with a bovine serum albumin concentra-
tion of 10% (RFU 2300). Ninety-six-well microtiter plates
were coated with AGE-albumin (50 mg/ml) for one hour at
37°C followed by an incubation period of three days at 4°C.
After washing with PBS, the plates were incubated with
0.4% BSA in PBS for two hours at room temperature to
prevent nonspecific binding. The AGE containing samples
were diluted in 0.4% BSA/PBS (1:10) and were incubated
in glass vials with the rabbit anti-AGE-RNAse antiserum
(1:1000) for one hour at 37°C and 16 hours at 4°C. These
mixtures (0.2 ml) were added to the AGE-albumin coated
wells and incubated for one hour at 37°C followed by a final
incubation step of 30 minutes at 4°C. After thorough
washing with PBS peroxidase labeled anti-rabbit antibody
(1:2000) was added for one hour at 37°C and 30 minutes at
4°C. Binding of the second antibody was determined by a
color reaction induced by the addition of ABTS (0.1%
solution in diluent buffer) and the measurement of the
optical density at 405 nm. The degree of inhibition of
anti-AGE antibody binding to the solid phase was propor-
tional to the AGE concentration of the sample. AGE-
modified b2-microglobulin (AGE-b2m, 25 mg/dl), which
was prepared under the same conditions as described for
AGE-RNAse, was used as a reference. Results were ex-
pressed in molar equivalents of AGE-b2m in relative
fluorescence units (RFU). The molar equivalent of AGE-
fibronectin was 25 to 34 mg/ml AGE-b2m, and 17 mg/ml for
AGE-albumin. Neither native albumin nor native fibronec-
tin showed any inhibition properties of AGE antibody
binding in the solid phase immunoassay.
Endothelial cell culture
Human umbilical cord vein endothelial cells (HUVEC)
were cultured according to Jaffe et al [21]. Briefly, cells
were pooled after collagenase treatment and seeded on
six-well cell culture plates coated with native fibronectin
(2.5 mg/cm2) or AGE-fibronectin (2.5 mg/cm2). Cells were
grown in RPMI 1640 medium supplemented with 20%
FCS, 1% L-glutamine, 100 U/ml penicillin G, 100 mg/ml
streptomycin and 1 mg/ml fungizone and after the first day
with 5% FCS under standard cell culture conditions (hu-
midified atmosphere, 5% CO2, 37°C). Reaching confluence
within three to four days, primary endothelial cell cultures
were used for all flow cytometric analyses and preparation
of total RNA. All cells showed cobblestone morphology
that did not differ between cells grown on native fibronectin
or AGE-fibronectin and showed uptake of acetylated LDL
and expression of von Willebrand factor and angiotensin
converting enzyme. The presence of contaminating CD14
positive cells (monocytes) was excluded by flow cytometry.
Immunofluorescence analysis of cellular adhesion
molecule expression
Endothelial cells were incubated in native fibronectin or
AGE-fibronectin coated six-well plates in RPMI 1640
medium containing either IL-1a (100 U/ml), TNF-a (500
U/ml), LPS (1 mg/ml), or AGE-albumin (500 mg/ml) or
medium alone (control) for four hours or 18 hours. After
incubation confluent HUVEC-monolayers were detached
by scraping with a rubber policeman in ice-cold PBS. Cells
were then washed twice and centrifuged at 300 g for 10
minutes. Fifty microliters of the cell suspension (5 3
AGE-FN1TNFa AGE-FN1LPS AGE-FN1sAGE
743 6 73 1218 6 129 124 6 12
113 6 15 156 6 18 81 6 8
n.d. n.d. 337 6 45
n.d. n.d. 169 6 18
238 6 20 266 6 29 136 6 4
384 6 36 418 6 23 143 6 14
n.d. n.d. 131 6 19
n.d. n.d. 147 6 29
854 6 86 1140 6 116 166 6 19
1170 6 139 1129 6 83 197 6 31
n.d. n.d. 226 6 36
n.d. n.d. 280 6 56
119 6 6 115 6 4 117 6 6
140 6 10 129 6 9 113 6 5
n.d. n.d. 93 6 14
n.d. n.d. 99 6 11
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105/ml) were incubated with 50 ml of the respective mono-
clonal antibody (mAb; 5 mg/ml) for 30 minutes at 4°C.
After washing, cells were stained with FITC-conjugated
goat F(ab9)2 anti-mouse IgG1IgM antibodies for 30 min-
utes at 4°C. Following two additional washing steps endo-
thelial cells were analyzed using a FACScan (Becton Dick-
inson, Mountain View, CA, USA) and the LYSIS II
software package (Becton Dickinson). The cell viability of
HUVEC prior to staining procedures was typically . 95%
as determined by trypan blue exclusion. Cytofluorimetric
analysis of cellular adhesion molecule cell surface expres-
sion was performed in a total of 10 independent cell culture
experiments. Data are given as mean fluorescence intensity
in percent of control expriments.
Semiquantitative reverse transcriptase-polymerase chain
reaction analysis of cell adhesion molecules
Human umbilical cord vein endothelial cells were cul-
tured on 175 cm2 cell culture flasks coated with native
fibronectin (2.5 mg/cm2) or AGE-fibronectin (2.5 mg/cm2)
in the presence of IL-1a (100 U/ml), AGE-albumin (500
mg/ml) or medium alone for 2.5 hours or 10 hours. After
incubation, cells were washed twice in diethylpyrocarbon-
ate-treated PBS and 1 3 107 cell aliquots were lysed by
addition of 1.8 ml RNazol-B. Total RNA was extracted as
described [22]. The quality of isolated RNA was controlled by
electrophoresis through formaldehyde agarose gels. High
quality RNA was quantitated by measuring absorption at
Fig. 1. Expression of E-selectin. (A) Surface
expression (mean fluorescence intensity, mfi) of
E-selectin on HUVEC cultured on native
fibronectin or on AGE-fibronectin after four
hours or 18 hours of incubation with IL-1a,
TNF-a, LPS, AGE-albumin (sAGE), or
medium as determined by flow cytometric
analysis. The results are given as percentages of
expression on non-stimulated HUVEC grown
on native fibronectin 6 SEM. P values (**P ,
0.01) refer to comparison of equally treated
cells grown on native fibronectin or AGE-
fibronectin. (B) Semiquantitative RT-PCR
analysis of E-selectin transcript levels in
endothelial cells. Cells were cultured on native
fibronectin or AGE-fibronectin for 2.5 hours or
10 hours with IL-1a, AGE-albumin (sAGE) or
medium alone. Results were corrected by the
ABL values of the respective cDNA. The
results are given as percentages of expression in
non-stimulated HUVEC grown on native
fibronectin 6 SEM. P values (*P , 0.05) refer
to comparison of equally treated cells grown on
native fibronectin or AGE-fibronectin.
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260 nm and 1 mg of total RNA was subjected to cDNA
synthesis as described elsewhere [23].
For semiquantitative analysis of PECAM, ICAM-1, E-
selectin and VCAM-1 mRNA, a RT-PCR protocol, which
allows measurement of relative transcript levels was ap-
plied [24]. The oligonucleotide primer sequences used for
PCR amplification of the respective mRNAs have been
previously described [25, 26]. Polymerase chain reaction
amplification of ABL transcripts was used as a reference to
assess variations of total RNA or cDNA between samples
as described previously [27]. The linear ranges of PCR
amplifications were established as a function of cycle
number and cDNA dilutions for each primer pair [24].
Reaction conditions included 3 ml cDNA, 10 to 50 pmol of
each primer, 2.5 to 3.0 mM MgCl2, 200 mM of each dNTP,
1.25 U Ampli-Taq DNA polymerase and a (32P)-dCTP
(150,000 cpm) in a 50 ml reaction volume. The thermal
cycling conditions were denaturation at 94°C (1 min),
annealing at 57°C 265°C (1 min) and extension at 72°C (1
min), preceded by an initial denaturation step at 94°C for
five minutes and followed by a terminal extension of 10
minutes at 72°C. The PCR amplification products were
subjected to 6% polyacrylamide gels and dried gels were
exposed to Kodak XAR-5 films at 270°C for 12 hours.
For quantification of PCR products incorporated a(32P)-
dCTP was measured on autoradiograms using an imaging
densitometer (model 670; BioRad Laboratories, Hercules,
CA, USA) and the system9s volume integration program
(BioRad Gel DOC 1000 system, Molecular Analyst/PC soft-
ware). Potential differences of total cellular RNA/cDNA in
Fig. 1. Continued.
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PCR analyses were corrected by dividing PECAM,
ICAM-1, E-selectin and VCAM-1 values by the ABL value
obtained from the respective cDNA. Each relative tran-
script level was measured in a total of 12 PCR analyses
using six cDNAs that were synthesized in duplicates from
RNAs of three independent cell culture experiments.
Transendothelial polymorphonuclear leukocyte migration
Isolation of polymorphonuclear leukocyte (PMNL) was
performed as described previously [28]. Briefly, heparin-
ized peripheral blood obtained from healthy volunteers was
layered over Ficoll-Paque (1.077 g/ml). After an initial
incubation step of 45 minutes at room temperature the
supernatants were layered on 63% Percoll underlayed with
72% Percoll. Following centrifugation at 500 g for 25
minutes at room temperature, cells were washed twice in
Ca21- and Mg21- free Hank’s solution. The cell pellets
were resuspended in RPMI 1640 medium at a final con-
centration of 2.5 3 106 cells/ml. The cell viability in all
experiments was . 95% as determined by trypan blue
exclusion.
Human umbilical vein endothelial cells were grown on
native fibronectin or AGE-fibronectin coated permeable
membrane inserts (diameter of 9 mm, pore size of 3.0 mm)
of a 24 multiwell double-chamber system and were subse-
quently incubated with IL-1a (100 U/ml) or medium (con-
trol) for four hours and 18 hours. Reaching confluence,
HUVEC monolayers of passages 2 to 4 were incubated with
PMNL (5 3 105) in the upper chambers of the permeable
inserts for two hours. At the end of the incubation period,
Fig. 2. Expression of ICAM-1. (A) Surface
expression (mean fluorescence intensity, mfi) of
ICAM-1 on HUVEC cultured on native
fibronectin or on AGE-fibronectin after four
hours or 18 hours of incubation with IL-1a,
TNFa, LPS, AGE-albumin (sAGE), or medium
as determined by flow cytometric analysis. The
results are given as percentages of expression
on non-stimulated HUVEC grown on native
fibronectin 6 SEM. P values (**P , 0.01) refer
to comparison of equally treated cells grown on
native fibronectin or AGE-fibronectin. (B)
Semiquantitative RT-PCR analysis of ICAM-1
transcript levels in endothelial cells. Cells were
cultured on native fibronectin or AGE-
fibronectin for 2.5 hours or 10 hours with IL-
1a, AGE-albumin (sAGE) or medium alone.
Results were corrected by the ABL values of
the respective cDNA. The results are given as
percentages of expression in non-stimulated
HUVEC grown on native fibronectin 6 SEM.
P values (*P , 0.05) refer to comparison of
equally treated cells grown on native fibronectin
or AGE-fibronectin.
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the membrane inserts containing the non-migrated leuko-
cytes were discarded. Without further washing or transfer
steps, migrated leukocytes in the lower chamber were
immediately exposed to 2 mM of the fluorescent dye
calcein-acetoxymethylester (calcein-AM). Following incu-
bation in the dark at room temperature for 30 minutes
(mild shaking), the relative fluorescence intensity was mea-
sured using the cytofluor 2350 fluorescence plate reader
(Millipore, Bedford, MA, USA). Absolute cell counts were
determined by comparison with dilution series of cal-
cein-AM labeled PMNLs cultured in RPMI 1640 medium
as described [29].
For blocking experiments, HUVEC were pre-incubated
for one hour with 300 ml of a mixture containing blocking
antibodies against PECAM (50 mg/ml), E-selectin (50
mg/ml), ICAM-1 (50 mg/ml) and VCAM-1 (60 mg/ml).
Fig. 2. Continued.
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Polymorphonuclear leukocytes were pre-treated with hu-
man IgG (10 mg/ml) at 37°C for one hour, to saturate
Fc-gamma receptors and to prevent nonspecific binding to
antibodies. Following preincubation, PMNL were coincu-
bated with HUVEC on the membrane inserts for two
hours. The number of transmigrated PMNL in individual
wells was determined as described above. Each experiment
was performed in triplicates for at least three times.
Statistical analyses
All data are presented as means 6 SEM. Statistical
analysis included ANOVA and Student’s t-test, which were
applied when appropriate.
RESULTS
AGE-fibronectin up-regulates cytokine induced
expression of endothelial cell adhesion molecules
The detailed results of flow cytometric analysis of cell
surface expression and of mRNA expression of endothelial
cell adhesion molecules are indicated in Table 1. Cell
surface expression of E-selectin, ICAM-1, and VCAM-1
was remarkably higher on HUVEC grown on AGE-fi-
bronectin after four hours of stimulation with IL-1a,
TNF-a or LPS, compared to HUVEC cultured on native
fibronectin as determined by flow cytometric analysis (Figs.
1, 2, and 3). Additionally, the presence of IL-1a led to a
Fig. 3. Expression of VCAM-1. (A) Surface
expression (mean fluorescence intensity; mfi) of
VCAM-1 on HUVEC cultured on native
fibronectin or on AGE-fibronectin after four
hours or 18 hours of incubation with IL-1a,
TNFa, LPS, AGE-albumin (sAGE), or medium
as determined by flow cytometric analysis. The
results are given as percentages of expression
on non-stimulated HUVEC grown on native
fibronectin 6 SEM. P values (*P , 0.05; **P ,
0.01) refer to comparison of equally treated
cells grown on fibronectin or AGE-fibronectin.
(B) Semiquantitative RT-PCR analysis of
VCAM-1 transcript levels in endothelial cells.
Cells were cultured on native fibronectin or
AGE-fibronectin for 2.5 hours or 10 hours with
IL-1a, AGE-albumin (sAGE) or medium alone.
Results were corrected by the ABL values of
the respective cDNA. The results are given as
percentages of expression in non-stimulated
HUVEC grown on native fibronectin 6 SEM. P
values (*P , 0.05) refer to comparison of
equally treated cells grown on fibronectin or
AGE-fibronectin.
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prolonged elevated E-selectin expression on HUVEC
grown on AGE-fibronectin compared to standard culture
conditions (Fig. 1). IL-1a, TNFa and LPS enhanced
ICAM-1 and VCAM-1 expression on HUVEC after 18
hours of culture on AGE-fibronectin (Figs. 2, 3). AGE-
fibronectin significantly up-regulated the IL-1a induced
expression of E-selectin mRNA at both timepoints,
whereas ICAM-1, and VCAM-1 transcripts were increased
after 2.5 hours (Figs. 1 to 3).
Neither AGE-fibronectin nor AGE-albumin nor a com-
bination of both enhanced the cell surface expression of
E-selectin in the absence of inflammatory stimuli (Fig. 1).
On the other hand, AGE-fibronectin alone increased the
surface expression of ICAM-1 or VCAM-1 on HUVEC
after four hours of culture. An additive effect of AGE-
albumin on AGE-fibronectin-induced ICAM-1 and
VCAM-1 surface expression and transcript levels was ob-
served after long-term incubation (Figs. 2 and 3), whereas
Fig. 3. Continued.
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the combination of AGE-albumin and AGE-fibronectin
and even AGE-fibronectin alone increased E-selectin tran-
script levels already after 2.5 hours. No significant addi-
tional effect of AGE-albumin on the expression of E-
selectin mRNA in HUVEC was observed at the later
timepoint (Fig. 1).
PECAM expression on HUVEC was slightly, but signif-
icantly enhanced by culture on AGE-fibronectin for four
hours and 18 hours with or without stimulating agents (Fig.
4). AGE-albumin showed a weak, but significant stimula-
tory effect on the PECAM transcript levels of endothelial
cells grown on AGE-fibronectin at either timepoint (Fig.
4). Most strikingly, IL-1a significantly reduced PECAM
mRNA expression independent from the presence of
AGE-fibronectin (Fig. 4).
Effect of AGE-fibronectin on transendothelial migration
of PMNLs
Confluent HUVEC monolayers grown on native fi-
bronectin or AGE-fibronectin were incubated for four
hours or 18 hours with IL-1a or with medium (control)
prior to co-incubation with PMNL. The spontaneous mi-
gration of unstimulated PMNL through HUVEC-monolay-
ers was increased about threefold if endothelial cells were
grown on AGE-fibronectin for four hours and 18 hours
compared to the migration pattern obtained on native
Fig. 4. Expression of PECAM. (A) Surface
expression (mean fluorescence intensity; mfi) of
PECAM on HUVEC cultured on native
fibronectin or on AGE-fibronectin after four
hours or 18 hours of incubation with IL-1a,
TNFa, LPS, AGE-albumin (sAGE), or medium
as determined by flow cytometric analysis. The
results are given as percentages of expression
on non-stimulated HUVEC grown on native
fibronectin 6 SEM. P values (*P , 0.05; **P ,
0.01) refer to comparison of equally treated
cells grown on native fibronectin or AGE-
fibronectin. (B) Semiquantitative RT-PCR
analysis of PECAM transcript levels in
endothelial cells. Cells were cultured on native
fibronectin or AGE-fibronectin for 2.5 hours or
10 hours with IL-1a, AGE-albumin (sAGE) or
medium alone. Results were corrected by the
ABL values of the respective cDNA. The
results are given as percentages of expression in
non-stimulated HUVEC grown on native
fibronectin 6 SEM. P values (*P , 0.05) refer
to comparison of equally treated cells grown on
native fibronectin or AGE-fibronectin.
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fibronectin (Fig. 5A). There was a fivefold increase of
PMNL migration through IL-1a activated endothelium
cultured on native fibronectin that was more than sevenfold
increased if endothelial cells were grown on AGE-fibronec-
tin (Fig. 5A). To demonstrate that the enhanced migration
of PMNLs is due to the AGE-fibronectin induced expres-
sion of cellular adhesion molecules, we performed addi-
tional migration experiments in the presence of a cocktail
containing blocking antibodies against E-selectin, ICAM-1,
VCAM-1, and PECAM. Blocking antibodies suppressed
PMNL migration through IL-1a stimulated endothelial
cells cultured on AGE-fibronectin to the levels of migration
through resting endothelial cells on AGE-fibronectin (Fig.
5B), whereas antibodies against endoglin (antibody 1G2)
and von Willebrand factor had no effect on PMNL migra-
tion (data not shown).
Fig. 4. Continued.
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DISCUSSION
The present study provides evidence that the interaction
of inflammatory mediators and glycated matrix proteins
results in a significant up-regulation of endothelial cell
adhesion structures and in a tremendous increase of the
transendothelial migration of PMNL.
It is well established that expression of cellular adhesion
molecules on endothelial cells is enhanced by various
cytokines during inflammation [9]. Furthermore, it has
been described that cellular adhesion molecules are present
on endothelial cells in atherosclerotic lesions [5, 7, 12].
Based on the observation that AGEs can be found in
diabetics and patients with uremia [15], the hypothesis was
raised that AGEs (matrix bound and soluble AGEs) could
modulate the cell surface expression of cellular adhesion
molecules in these patients. In particular, we were inter-
ested in the effect of AGEs on endothelial cell surface and
mRNA expression of cellular adhesion molecules in the
presence of inflammatory stimuli, since patients with dia-
betes mellitus and uremia frequently experience inflamma-
tory episodes.
In the present study, we observed that AGE-matrix
together with inflammatory stimuli significantly increased
the cell surface expression of E-selectin, ICAM-1 and
VCAM-1. Furthermore, a combination of AGE-albumin
and matrix bound AGEs enhanced the cell surface expres-
sion of ICAM-1 and VCAM-1. This effect of AGE-albumin
was not observed for E-selectin. If endothelial cells were
exposed to AGE-fibronectin alone, a significant up-regula-
tion of ICAM-1 and VCAM-1 was observed (although to a
much lesser extent), but not of E-selectin. At the molecular
level, we could demonstrate that mRNA levels of E-
selectin, ICAM-1 and VCAM-1 significantly increased fol-
lowing short-time stimulation of endothelial cells with
matrix bound AGEs and inflammatory mediators.
Furthermore, the combination of AGE-albumin and
Fig. 5. Effect of AGE-fibronectin on transendothelial migration of PMNLs. Confluent HUVEC monolayers grown on native fibronectin (M) or
AGE-fibronectin (o) were incubated for four hours or 18 hours with IL-1a or with medium (Control) prior to co-incubation with 5 3 105 PMNL in
a double chamber system. Results are shown as number of migrated PMNL 6 SEM. (A) Migration of PMNL through HUVEC monolayers. *P , 0.05
refers to comparison between the numbers of migrated PMNL through equally treated HUVEC grown on native fibronectin or AGE-fibronectin. (B)
Blocking experiments. Incubation of HUVEC monolayers with a cocktail of mAbs against PECAM, ICAM-1, E-selectin and VCAM-1 for one hour after
incubation with medium (Control) or IL-1a and prior to co-incubation with PMNL. #P , 0.05 refers to comparison between the numbers of migrated
PMNL through equally treated HUVEC grown on the same type of fibronectin with blocking mAbs (B) versus incubation without blocking mAbs (A).
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AGE-fibronectin also resulted in an increase of ICAM-1,
VCAM-1 and E-selectin transcript levels.
Several studies demonstrated that AGE-albumin en-
hances cell surface expression of endothelial ICAM-1 and
VCAM-1 [30–32]. In our study, AGE-albumin enhanced
the expression of ICAM-1 and VCAM-1 on endothelial
cells grown on AGE-fibronectin, but not on endothelial
cells cultured on native fibronectin. This discrepancy might
be due to the different degrees of long-term glycation used
in these studies. The concentration of albumin (500 mg/ml)
in our study was higher than that used by Schmidt et al [32].
Though our albumin concentration was high, fluorescence
intensity was low compared to that of AGE-fibronectin
(2300 RFU vs. 15000 RFU, respectively). The fluorescence
intensity of the AGE-albumin used in the present study,
however, resembles the in vivo situation, where proteins
with longer half life (such as, fibronectin) may be prone to
more intense glycation compared to proteins with shorter
half life (for example, serum albumin). Furthermore, we
used G-6-P instead of glucose for in vitro glycation. Since
proteins in diabetic patients are chronically exposed to
hyperglycemic conditions for many years, we took highly
concentrated (0.5 M) G-6-P as used by others [33] to
achieve comparable in vitro glycation in a relatively short
time.
In addition to E-selectin, ICAM-1 and VCAM-1, we
show that matrix bound AGEs also enhanced the endothe-
lial cell surface expression of PECAM in the presence of
inflammatory mediators. This up-regulatory effect was also
observed on endothelial cells cultured on AGE-fibronectin
in the presence of AGE-albumin. At the gene transcript
level we demonstrate that an inflammatory stimulus, such
as IL-1a, led to a significant reduction of PECAM mRNA
levels, probably due to enhanced translational and cell
surface expression activities at the time points investigated
in this study.
An interesting finding of the present study is the time
dependent modulatory effect of AGE-fibronectin on the
surface expression of cellular adhesion molecules. Cell
adhesion molecules are responsible for different sequential
steps in the leukocyte diapedesis process. E-selectin is
involved in “rolling,” ICAM-1 and VCAM-1 in “firm
adhesion” and PECAM, ICAM-1 and VCAM-1 in “trans-
endothelial migration” of leukocytes [34, 35]. Our results
indicate that the cooperation of inflammatory cytokines
and AGE-fibronectin leads to a prolonged expression of
“early” endothelial adhesion molecules and to a premature
expression of “late” adhesion molecules. The co-stimula-
tion via AGE-fibronectin and IL-1a, which is supposed to
frequently occur in diabetic or renal failure patients, sug-
gests a mechanism that enhances leukocyte recruitment to
the blood vessel wall and finally may be involved in the
acceleration of atherogenesis [20, 21].
Migration of leukocytes across the endothelial barrier is
one of the key events in atherosclerotic plaque formation
[4, 36]. Therefore, we studied transendothelial migration of
PMNLs following activation of endothelial cells with IL-1a
and observed a more than sevenfold increase in PMNL
migration if endothelial cells were grown on AGE-fi-
bronectin. These results demonstrate that the exposure of
endothelial cells to AGE-fibronectin enhances the cyto-
kine-induced transendothelial migration of PMNL.
From previous studies with mononuclear phagocytes and
AGE-albumin it seems likely that monocytes are able to
adhere to and migrate through AGE modified endothelium
[37]. They are retained in the subendothelial space due to
a chemotactic effect of AGEs and the expression of recep-
tors for AGE and CD49d/29. In the present study, we have
used PMNL since they lack AGE-receptors and fibronec-
tin-receptors (CD49d/29, VLA-4). Therefore, they could
not be captured by fibronectin or AGE in our migration
assay. Since AGE-compounds were described to have
chemotactic effects on leukocytes [37], we performed
blocking experiments, which clearly confirmed the involve-
ment of IL-1a and AGE-fibronectin induced up-regulation
of cellular adhesion molecule expression on HUVEC in
transendothelial migration. Furthermore, in our study,
growing endothelial cells on AGE-fibronectin did not result
in enhanced production of IL-8 (data not shown), which is
a potent chemoattractant for PMNL [38].
Studies from other groups demonstrated that advanced
glycation of fibronectin does not alter the adhesion prop-
erties of endothelial cells on this growth surface and it does
not modify spreading of HUVEC in cell culture experi-
ments [33]. Therefore, the augmented transendothelial
migration of PMNL cannot be explained by increased
porosity of the endothelial cell monolayers. We therefore
conclude that the increased transendothelial migration of
PMNL through AGE-fibronectin versus native fibronectin
in our experiments is due to cellular adhesion molecule-
related interactions and was not due to chemotactic factors
or structural alterations of the endothelial cell monolayer.
Adhesion of PMNL to endothelial cells and their matrix
proteins as well as transendothelial migration of PMNL has
recently received considerable interest in the pathogenesis
of atherosclerotic lesions [4, 39, 40]. PMNL can release
mediators including oxygen-derived free radicals, resulting
in an impairment of endothelial cell function [41]. The
damaged endothelium then exposes receptors for immuno-
globulins and complement, which further promote adher-
ence of PMNL to endothelial cells [42]. The terminal C5b-9
complement complex has been localized in atherosclerotic
plaques, indicating that complement activation had oc-
curred. This process was mediated by activation of PMNL
[42]. Furthermore, it has been shown that PMNL cause
endothelial dysfunction during ischemia and are involved in
reperfusion injury [4]. Thus, our data support the concept
that the interaction of leukocytes with endothelial cells
exposed to glycated matrix proteins and inflammatory
mediators is putatively involved in the development of
Sengoelge et al: AGE-modified fibronectin and inflammation 1649
vascular pathology. These findings suggest some clinical
importance of AGEs and inflammatory mediators, espe-
cially in patients with recurrent acute infectious episodes.
It was not the purpose of the present study to clarify the
regulatory mechanisms of AGE modulated mRNA and
protein expression of endothelial cellular adhesion mole-
cules. According to Stern and colleagues [43], however, the
NF-kB/IkBa system has been suggested to participate in
the regulation of the expression of these molecules. It has
been shown that IkBa is capable of displacing NF-kB
p50/p65 from E-selectin- and VCAM-1 NF-kB binding
elements, thereby negatively regulating the expression of
these molecules. It might be possible that signaling via
AGE proteins/AGE receptors influences this negative reg-
ulatory process that is supposed to prevent the inappropri-
ate expression of adhesion molecules. By offsetting the
physiologic and dynamic balance of the NF-kB/IkBa sys-
tem, AGEs might promote the onset and the perpetuation
of vascular disease. Another potential candidate for medi-
ating AGE effects is the cytokine-induced enhancer com-
plex, which provides an attractive model for superinduction
of endothelial adhesion structures by the complex interac-
tion of multiple transcription regulatory elements [44].
In conclusion, this is the first study to our knowledge
demonstrating that the effect of an AGE-modified matrix
protein, AGE-fibronectin, in combination with inflamma-
tory stimuli, enhances the endothelial cellular adhesion
molecule expression and augments transmigration of
PMNL through cytokine activated endothelial cells. We
provide evidence that irreversibly glycated matrix protein
fibronectin modulates the endothelial expression of E-
selectin, ICAM-1, VCAM-1 and PECAM both on the cell
surface expressed protein and the mRNA-level, an effect
that is enhanced by the presence of inflammatory stimuli.
The irreversibly glycated matrix compound fibronectin
caused a dramatic increase of transendothelial migration of
PMNL. These findings represent a potentially important
link between glycated matrix proteins, inflammation, and
activation of the endothelial adhesion cascade that may be
involved in vascular pathology contributing to the develop-
ment of the excess atherosclerotic burden in patients with
diabetes mellitus or chronic renal failure.
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